Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 3Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 3

Conditions

Mesothelioma, Malignant 3Melanoma 2Squamous Cell Carcinoma of Head and Neck 1Platinum-resistant Recurrent Ovarian Cancer 1Lung Neoplasms 1Laryngeal Diseases 1Kidney Neoplasms 1Esophageal Squamous Cell Carcinoma 1EGFR Mutant Advanced Non Small Cell Lung Cancer 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 4tremelimumab 3Pemetrexed 3durvalumab 2atezolizumab 2Radiotherapy 2Nivolumab 2Mitomycin 2Doxorubicin 2toripalimab 1talazoparib 1rucaparib 1regorafenib 1ranpirnase 1pembrolizumab 1niraparib 1liposomal doxorubicin 1dostarlimab 1cemiplimab 1bemcentinib 1avelumab 1abemaciclib 1Vinorelbine 1Vinblastine 1Thiostrepton 1Surgical Procedures, Operative 1Oxaliplatin 1One-Lung Ventilation 1Neoadjuvant Therapy 1Megestrol Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Mesothelioma, Malignant × tremelimumab × Clear all
NCT02588131 2015-10-27

A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)

Italian Network for Tumor Biotherapy Foundation

Phase 2 Unknown
40 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT01655888 2012-08-02

The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma

Azienda Ospedaliera Universitaria Senese

Phase 2 Unknown
29 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT01649024 2012-07-25

A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma

Azienda Ospedaliera Universitaria Senese

Phase 2 Unknown
29 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡